Verseon Corporation announced that Dr. Robert Karr has accepted the nomination for a position on the Verseon Board of Directors. His appointment is subject to approval at a Special Shareholder Meeting for the election of a Class II Director, which will be held at 7100 Stevenson Blvd, Fremont, CA 94538 on October 19, 2017 at 2 p.m. local time, and the completion of customary UK regulatory requirements. Alastair Cade, a Class II Non-Executive Director of the Company, has stepped down from his position on the Board of Directors with immediate effect. Dr. Robert Karr, the former Senior Vice President of R&D Strategy at Pfizer, is currently the Chief Scientific Officer at Tioma, an immuno-oncology company developing antibody treatments for solid and hematologic cancers. During his extensive career in the pharmaceutical industry, Dr. Karr has held various senior executive positions at Idera Pharmaceuticals, Pfizer, and Warner-Lambert. Prior to his career in industry.